📈 Live Market Tracking
Every NSE and BSE corporate filing, read and explained by AI within minutes — impact, key figures, short/long-term view and what to watch.
Live · AI analyzer runs every 5 min (07:00–23:55 IST)
Latest filing: 2026-09-22 17:51
0 analysed today
FollowTelegram
0
Today
152,139
All-time analysed
43,645
Positive
6,747
Negative
92,898
Neutral
8,781
Watch
📊 Last 7 days — analysed filings by sentiment
Note: These are AI-generated, educational summaries of public NSE
filings — grounded in each document, but not investment advice and possibly incomplete.
Verify against the original filing and consult a SEBI-registered adviser before acting.
5 announcements match the current filters (relevance ≥ 5).
Ishita Drugs secures Rs 11.75 Cr credit facilities from HDFC Bank for Schedule M capex
Ishita Drugs & Industries has entered into a loan agreement with HDFC Bank Limited to avail credit facilities totaling Rs 11.75 crore. The financing includes a term loan of Rs 9.75 crore and a working capital facility of Rs 2.00 crore. The funds are earmarked for upgrading its manufacturing facility at Sanand, Gujarat, to comply with Revised Schedule M standards. At Rs 11.75 crore, this debt facility is highly material, representing nearly 98% of its TTM revenue of Rs 12 crore and about 98% of its net worth of Rs 12 crore.
Confidence: HIGH
What changedSecured Rs 11.75 crore bank financing (Rs 9.75 crore term loan, Rs 2.00 crore working capital) from HDFC Bank.
Why it mattersEnables compliance with mandatory Revised Schedule M norms to maintain operations and drug manufacturing licenses, but significantly alters the company's virtually debt-free balance sheet.
Total Credit Facility: Rs 11,75,00,000Term Loan Component: Rs 9,75,00,000Working Capital Facility: Rs 2,00,00,000Facility vs TTM Revenue: ~98%Facility vs Net Worth: ~98%
📅 Short termEnsures regulatory continuity without diluting equity, though investors will closely watch the pace of drawdown and interest expense commencement.
📈 Long termBrings the Sanand manufacturing facility up to modern regulatory standards necessary to sustain operations, though debt servicing will weigh on future cash flows given historical annual PAT of under Rs 1 crore.
⚠ Risk flags
- High leverage addition relative to scale: debt facility nearly equals existing net worth and annual revenue
- Execution and downtime risk during facility upgradation
Key Highlights
Total credit facility of Rs 11.75 crore executed with HDFC Bank on 22.09.2026
Facility comprises a Rs 9.75 crore term loan and a Rs 2.00 crore working capital limit
Proceeds to fund plant upgradation to meet Revised Schedule M pharma compliance at Sanand, Gujarat
Secured by a first charge on immovable and movable assets at Sanand facility; current outstanding is Nil
👀 What to Watch
Track the deployment schedule of the capex, completion timelines for the Revised Schedule M upgrades, and the impact of subsequent interest costs on quarterly margins.
Ishita Drugs Approves ₹11.75 Cr Borrowing from HDFC Bank (Nearly 100% of TTM Revenue)
Ishita Drugs & Industries Ltd has approved credit facilities totaling ₹11.75 crore from HDFC Bank Ltd. The borrowing comprises a term loan of ₹9.75 crore and a working capital facility of ₹2.00 crore based on HDFC Bank's sanction letter dated September 17, 2026. This is a very significant leverage increase for the micro-cap pharma company, as the facility represents roughly 98% of its TTM revenue (₹12 crore) and matches its net worth of ₹12 crore, shifting its previously debt-free balance sheet.
Confidence: HIGH
What changedThe Board approved raising ₹11.75 crore in debt financing (term loan plus working capital) from HDFC Bank.
Why it mattersThe company was virtually debt-free (D/E of 0.01); taking on ₹11.75 crore in debt on a net worth of ₹12 crore will substantially elevate financial leverage and interest costs, while providing capital for operations or capex.
Total Approved Borrowing: Rs. 11,75,00,000Term Loan: Rs. 9,75,00,000Working Capital Facility: Rs. 2,00,00,000Sanction Letter Date: 17.09.2026Borrowing vs TTM Revenue: ~98%Borrowing vs Net Worth: ~98%
📅 Short termInvestors will assess whether the substantial debt commitment is aimed at a major growth expansion or operational strain, keeping an eye on immediate cash flow demands.
📈 Long termIf the ₹9.75 crore term loan is deployed into productive, margin-accretive assets, it could expand the current ₹12-15 crore annual revenue base, but failure to execute creates sharp solvency and interest servicing risks given TTM PAT is only ₹1 crore.
⚠ Risk flags
- Sharp increase in leverage on a net worth of ₹12 Cr and TTM PAT of only ₹1 Cr
- Specific end-use and interest rate terms of the term loan were not detailed in the filing
Key Highlights
Total borrowing approved: ₹11,75,00,000 (₹11.75 crore) from HDFC Bank Limited
Facility split: ₹9,75,00,000 (₹9.75 crore) Term Loan and ₹2,00,00,000 (₹2.00 crore) Working Capital
Terms governed by HDFC Bank's Sanction Letter dated September 17, 2026
Borrowing is within limits approved under Section 180(1)(c) at AGM held on September 30, 2024
👀 What to Watch
Watch for disclosures on the exact end-use of the ₹9.75 crore term loan (such as capex or facility modernization) and monitor interest cost impacts on net margins in future quarters.
Ishita Drugs Commits Rs 10 Cr to Facility Upgradation; Re-appoints Director
Ishita Drugs has announced a major manufacturing facility upgradation to comply with Revised Schedule M standards, involving a total commitment of approximately Rs 10 crore. To date, the company has spent Rs 4.35 crore on civil works and a new warehouse, with another Rs 5.65 crore in equipment orders issued. This project is highly material, representing approximately 67% of the company's TTM revenue of Rs 15 crore and 83% of its net worth. The board also approved the re-appointment of promoter Mrs. Abha Agrawal as a director and is currently negotiating with banks for project financing.
Confidence: HIGH
What changedThe company provided a concrete financial update on its ongoing facility upgradation and formalized the re-appointment of a key promoter-director.
Why it mattersThe Rs 10 crore investment is a major undertaking for a company with a Rs 23 crore market cap, aimed at meeting revised regulatory standards (Schedule M) which is critical for continued operations and potential growth in the pharma sector.
Capex spent to date: Rs 4.35 crCapital contracts issued: Rs 5.65 crTotal project vs TTM Revenue: ~67%Total project vs Net Worth: ~83%Market Capitalization: Rs 23 cr
📅 Short termPositive sentiment expected as the company demonstrates commitment to regulatory compliance and capacity expansion, though funding details remain a key variable.
📈 Long termStructural improvement in manufacturing capabilities and regulatory compliance, though debt levels may rise if bank financing is secured for this large-scale project.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Funding risk (bank negotiations ongoing)
- Execution risk for the upgradation project
- High concentration of promoter family in management
Key Highlights
Rs 4.35 crore already spent on renovation of existing buildings and construction of a new warehouse block.
Rs 5.65 crore in capital contracts and orders issued for various utilities and equipment.
Total project commitment of ~Rs 10 crore represents ~67% of TTM revenue (Rs 15 Cr).
Re-appointment of Mrs. Abha Agrawal as Non-Executive Director notwithstanding her attaining the age of 75 years.
Company is actively negotiating with banks to raise funds for financing the remaining upgradation project.
👀 What to Watch
Monitor the successful closure of bank financing for the project and the timeline for completion of the manufacturing facility extension to ensure no regulatory disruptions.
Rs 10 Cr Capex for Facility Upgradation; Q1 FY27 Results Approved
Ishita Drugs & Industries has announced a major manufacturing facility upgradation project to comply with Revised Schedule M standards. The company has already spent Rs 4.35 crore on renovation and new construction, with an additional Rs 5.65 crore in capital contracts already issued. This total commitment of Rs 10 crore is highly significant, representing approximately 67% of the company's TTM revenue of Rs 15 crore. The company is currently negotiating with banks to secure financing for the project.
Confidence: HIGH
What changedThe company has moved into the execution phase of a major facility upgrade, committing capital equivalent to a significant portion of its annual revenue.
Why it mattersFor a micro-cap company with Rs 15 cr revenue, a Rs 10 cr investment is transformative. Compliance with Revised Schedule M is essential for regulatory standing and can potentially lead to higher-margin business or export opportunities.
Capex spent to date: Rs 4.35 crCapital contracts issued: Rs 5.65 crTotal Project vs TTM Revenue: ~67%Total Project vs Net Worth: ~83%TTM Revenue: Rs 15 cr
📅 Short termThe market is likely to view the substantial capex commitment as a sign of long-term growth intent, though the lack of specific Q1 P&L figures in the text may limit immediate momentum.
📈 Long termIf executed successfully, the upgraded facility could re-rate the business by allowing it to handle more complex pharmaceutical manufacturing and meet stricter regulatory requirements.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Execution risk of the ongoing construction
- Financing risk as bank negotiations are still active
- Potential for increased interest costs given the current zero-debt status
Key Highlights
Rs 4.35 crore already spent on renovation of existing buildings and construction of new blocks
Rs 5.65 crore in capital contracts and orders issued for utilities and equipment
Total project visibility of Rs 10 crore represents ~67% of TTM revenue (Rs 15 cr)
Upgradation project is aimed at compliance with Revised Schedule M manufacturing standards
Board approved re-appointment of promoter Mrs. Abha Agrawal as Non-Executive Director
👀 What to Watch
Monitor the successful closure of bank financing and the timeline for the completion of the manufacturing facility upgrade. Watch for any impact on production during the renovation phase in upcoming quarterly results.
Ishita Drugs to invest ₹10 Cr in facility upgrade; ₹4.35 Cr already spent
Ishita Drugs & Industries has announced a significant manufacturing facility upgrade to comply with Revised Schedule M standards. The company has already spent ₹4.35 crore on construction and has issued capital contracts worth ₹5.65 crore for equipment and utilities. This total project outlay of ₹10 crore is highly material, representing approximately 67% of the company's TTM revenue of ₹15 crore. The board also approved Q1 FY27 results and is currently negotiating with banks to secure funding for the project.
Confidence: HIGH
What changedThe company has moved from planning to active execution of a major facility upgrade, with nearly half the projected capital already deployed or committed.
Why it mattersCompliance with Revised Schedule M is a regulatory necessity in pharma; the scale of this investment relative to the company's size suggests a significant modernization that could enhance operational capabilities.
Total Project Outlay: ₹10 crAmount Spent to Date: ₹4.35 crNew Capital Contracts: ₹5.65 crProject vs TTM Revenue: ~67%Project vs Market Cap: ~43%
📅 Short termThe market may react positively to the scale of the upgrade, though the impact of Q1 FY27 results (approved but not detailed in text) will be the immediate driver.
📈 Long termIf successfully funded and executed, this upgrade modernizes the asset base of a micro-cap company, though it will likely introduce debt to a currently debt-free balance sheet.
⚠ Risk flags
🔬 Flagged for deeper Multibagger analysis — view briefs →
- Funding risk (bank negotiations ongoing)
- Execution risk of manufacturing upgrade
- Potential increase in leverage for a micro-cap
Key Highlights
₹435 lakh (₹4.35 cr) already spent towards renovation and construction of new blocks
₹565 lakh (₹5.65 cr) in capital contracts and orders issued for utilities and equipment
Total project visibility of ₹10 cr represents ~67% of TTM revenue and ~43% of market cap
Construction of a new warehouse block has been completed as part of the ongoing upgrade
Board approved re-appointment of promoter-director Mrs. Abha Agrawal post attaining age 75
👀 What to Watch
Watch for the successful closure of bank financing negotiations and the completion timeline for the remaining civil works on existing buildings.
